全文获取类型
收费全文 | 33347篇 |
免费 | 2157篇 |
国内免费 | 96篇 |
专业分类
耳鼻咽喉 | 489篇 |
儿科学 | 828篇 |
妇产科学 | 475篇 |
基础医学 | 4017篇 |
口腔科学 | 451篇 |
临床医学 | 3610篇 |
内科学 | 6691篇 |
皮肤病学 | 420篇 |
神经病学 | 2930篇 |
特种医学 | 1344篇 |
外科学 | 5654篇 |
综合类 | 379篇 |
一般理论 | 40篇 |
预防医学 | 2947篇 |
眼科学 | 514篇 |
药学 | 2532篇 |
中国医学 | 30篇 |
肿瘤学 | 2249篇 |
出版年
2023年 | 223篇 |
2022年 | 181篇 |
2021年 | 834篇 |
2020年 | 620篇 |
2019年 | 970篇 |
2018年 | 1162篇 |
2017年 | 811篇 |
2016年 | 808篇 |
2015年 | 977篇 |
2014年 | 1469篇 |
2013年 | 1933篇 |
2012年 | 2796篇 |
2011年 | 2862篇 |
2010年 | 1498篇 |
2009年 | 1388篇 |
2008年 | 2394篇 |
2007年 | 2335篇 |
2006年 | 2148篇 |
2005年 | 2170篇 |
2004年 | 2041篇 |
2003年 | 1823篇 |
2002年 | 1679篇 |
2001年 | 182篇 |
2000年 | 163篇 |
1999年 | 197篇 |
1998年 | 264篇 |
1997年 | 190篇 |
1996年 | 188篇 |
1995年 | 156篇 |
1994年 | 161篇 |
1993年 | 135篇 |
1992年 | 79篇 |
1991年 | 76篇 |
1990年 | 66篇 |
1989年 | 63篇 |
1988年 | 50篇 |
1987年 | 41篇 |
1986年 | 30篇 |
1985年 | 37篇 |
1984年 | 50篇 |
1983年 | 55篇 |
1982年 | 68篇 |
1981年 | 44篇 |
1980年 | 31篇 |
1979年 | 21篇 |
1978年 | 20篇 |
1977年 | 17篇 |
1976年 | 12篇 |
1975年 | 13篇 |
1974年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Olascoaga-Del Angel Kevin Samael Gutierrez Humberto Knigsberg Mina Prez-Villanueva Jaime Lpez-Diazguerrero Norma Edith 《Biogerontology》2022,23(4):453-471
Biogerontology - Senescent cells accumulate within tissues during aging and secrete an array of pro-inflammatory molecules known as senescent-associated secretory phenotype (SASP), which contribute... 相似文献
4.
Kevin Kyung Ho Choi Santosh Sanagapalli 《World journal of gastrointestinal oncology》2022,14(3):568-586
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Progression to cancer typically occurs in a stepwise fashion through worsening dysplasia and ultimately, invasive neoplasia. Established EAC with deep involvement of the esophageal wall and/or metastatic disease is invariably associated with poor long-term survival rates. This guides the rationale of surveillance of Barrett’s in an attempt to treat lesions at an earlier, and potentially curative stage. The last two decades have seen a paradigm shift in management of Barrett’s with rapid expansion in the role of endoscopic eradication therapy (EET) for management of dysplastic and early neoplastic BE, and there have been substantial changes to international consensus guidelines for management of early BE based on evolving evidence. This review aims to assist the physician in the therapeutic decision-making process with patients by comprehensive review and summary of literature surrounding natural history of Barrett’s by histological stage, and the effectiveness of interventions in attenuating the risk posed by its natural history. Key findings were as follows. Non-dysplastic Barrett’s is associated with extremely low risk of progression, and interventions cannot be justified. The annual risk of cancer progression in low grade dysplasia is between 1%-3%; EET can be offered though evidence for its benefit remains confined to highly select settings. High-grade dysplasia progresses to cancer in 5%-10% per year; EET is similarly effective to and less morbid than surgery and should be routinely performed for this indication. Risk of nodal metastases in intramucosal cancer is 2%-4%, which is comparable to operative mortality rate, so EET is usually preferred. Submucosal cancer is associated with nodal metastases in 14%-41% hence surgery remains standard of care, except for select situations. 相似文献
5.
Josupeit Jan Dadaczynski Kevin Quilling Eike 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2022,65(7-8):829-835
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Die Schule ist einer der wichtigsten Orte, an dem die Förderung der Gesundheit von Kindern und Jugendlichen ansetzen kann,... 相似文献
6.
Lombardo Joseph Ko Kevin Shimada Ayako Nelson Nicolas Wright Christopher Chen Jerry Maity Alisha Ruggiero Marissa L. Richard Scott Papanagnou Dimitrios Mitchell Edith Leader Amy Simone Nicole L. 《Cancer causes & control : CCC》2022,33(4):559-582
Cancer Causes & Control - A disparity exists in cancer screening rates for the Sexual and Gender Minority (SGM) community. We sought to understand the perceptions and baseline knowledge of... 相似文献
7.
Tara O. Henderson MD MPH Brynn W. Fowler MPH Haley A. Hamann MPH Paul C. Nathan MD MSc Jillian Whitton MS Wendy M. Leisenring ScD Kevin C. Oeffinger MD Joseph P. Neglia MD MPH Lucie M. Turcotte MD MPH MS Michael A. Arnold MD PhD Miriam R. Conces MD Rebecca M. Howell PhD Leslie L. Robison PhD Gregory T. Armstrong MD MSCE Kenneth A. Alexander MD PhD 《Cancer》2022,128(2):373-382
8.
Haichen Zhang Kevin Colclough Anna L. Gloyn Toni I. Pollin 《The Journal of clinical investigation》2021,131(3)
Monogenic diabetes refers to diabetes mellitus (DM) caused by a mutation in a single gene and accounts for approximately 1%–5% of diabetes. Correct diagnosis is clinically critical for certain types of monogenic diabetes, since the appropriate treatment is determined by the etiology of the disease (e.g., oral sulfonylurea treatment of HNF1A/HNF4A-diabetes vs. insulin injections in type 1 diabetes). However, achieving a correct diagnosis requires genetic testing, and the overlapping of the clinical features of monogenic diabetes with those of type 1 and type 2 diabetes has frequently led to misdiagnosis. Improvements in sequencing technology are increasing opportunities to diagnose monogenic diabetes, but challenges remain. In this Review, we describe the types of monogenic diabetes, including common and uncommon types of maturity-onset diabetes of the young, multiple causes of neonatal DM, and syndromic diabetes such as Wolfram syndrome and lipodystrophy. We also review methods of prioritizing patients undergoing genetic testing, and highlight existing challenges facing sequence data interpretation that can be addressed by forming collaborations of expertise and by pooling cases. 相似文献
9.
Hanchen Xu Kevin Van der Jeught Zhuolong Zhou Lu Zhang Tao Yu Yifan Sun Yujing Li Changlin Wan Ka Man So Degang Liu Michael Frieden Yuanzhang Fang Amber L. Mosley Xiaoming He Xinna Zhang George E. Sandusky Yunlong Liu Samy O. Meroueh Chi Zhang Aruna B. Wijeratne Cheng Huang Guang Ji Xiongbin Lu 《The Journal of clinical investigation》2021,131(10)
One of the primary mechanisms of tumor cell immune evasion is the loss of antigenicity, which arises due to lack of immunogenic tumor antigens as well as dysregulation of the antigen processing machinery. In a screen for small-molecule compounds from herbal medicine that potentiate T cell–mediated cytotoxicity, we identified atractylenolide I (ATT-I), which substantially promotes tumor antigen presentation of both human and mouse colorectal cancer (CRC) cells and thereby enhances the cytotoxic response of CD8+ T cells. Cellular thermal shift assay (CETSA) with multiplexed quantitative mass spectrometry identified the proteasome 26S subunit non–ATPase 4 (PSMD4), an essential component of the immunoproteasome complex, as a primary target protein of ATT-I. Binding of ATT-I with PSMD4 augments the antigen-processing activity of immunoproteasome, leading to enhanced MHC-I–mediated antigen presentation on cancer cells. In syngeneic mouse CRC models and human patient–derived CRC organoid models, ATT-I treatment promotes the cytotoxicity of CD8+ T cells and thus profoundly enhances the efficacy of immune checkpoint blockade therapy. Collectively, we show here that targeting the function of immunoproteasome with ATT-I promotes tumor antigen presentation and empowers T cell cytotoxicity, thus elevating the tumor response to immunotherapy. 相似文献